Safety of combining radiation therapy and antibody-drug conjugates in patients with breast cancer: a systematic review and meta-analysis
Take-home: This systematic review and meta-analysis of 29 studies involving 3,817 patients evaluated the safety of combining radiotherapy (RT) with antibody-drug conjugates (ADCs) in #BreastCancer Severe extracranial toxicities were uncommon with T-DM1, T-DXd, and sacituzumab govitecan (SG). However, intracranial RT revealed a consistent radiation necrosis safety signal with T-DM1, not observed with T-DXd or SG. These findings inform clinical decision-making and support updated ESTRO consensus recommendations. Courtesy of mirrors of medicine
About this highlight
Safety of combining radiation therapy and antibody-drug conjugates in patients with breast cancer: a systematic review and meta-analysis
Luca Visani, Carlotta Becherini, Marcin Kubeczko, Saverio Caini, Sara Alkner, Cristina Saura, Angelika M. Starzer, Liesbeth J. Boersma, Evandro de Azambuja, Nadia Harbeck, Hilary Stobart, Tanja Spanic, Charlotte E. Coles, Javier Cortés, Giuseppe Curigliano, Clare M. Isacke, Stephen P. Jackson, Christopher M. Jones, Orit Kaidar-Person, Matteo Lambertini, Elisabetta Marangoni, Andrea Morandi, Birgitte Offersen, Shani Paluch-Shimon, Hope Rugo, Lorenzo Livi, Philip Poortmans, Icro Meattini. Radiotherapy & Oncology
- Type
- Publication pick
- Topic
- Breast
